التفاصيل البيبلوغرافية
| العنوان: |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. |
| المؤلفون: |
Grünwald, Viktor1,2 (AUTHOR) gruenwald.viktor@mh-hannover.de, Chirovsky, Diana1,3 (AUTHOR) diana.chirovsky@merck.com, Cheung, Winson Y.4,5 (AUTHOR) winson.cheung@ahs.ca, Bertolini, Federica6 (AUTHOR) bertolini.federica@policlinico.mo.it, Ahn, Myung-Ju7 (AUTHOR) silkahn@skku.edu, Yang, Muh-Hwa8 (AUTHOR) mhyang2@vghtpe.gov.tw, Castro, Gilberto9 (AUTHOR) gilberto.cjunior@hsl.org.br, Berrocal, Alfonso10 (AUTHOR) berrocal_alf@gva.es, Sjoquist, Katrin11,12 (AUTHOR) katrin.sjoquist@ctc.usyd.edu.au, Kuyas, Hélène13 (AUTHOR) helene.kuyas@kantarhealth.com, Auclair, Valérie13 (AUTHOR) valerie.auclair@kantarhealth.com, Guillaume, Xavier13 (AUTHOR) xavier.guillaume@kantarhealth.com, Joo, Seongjung3 (AUTHOR) seongjung.joo@merck.com, Shah, Roshani3 (AUTHOR) roshani1130@gmail.com, Harrington, Kevin14 (AUTHOR) Kevin.Harrington@icr.ac.uk, GLANCE H&N STUDY Investigators (CORPORATE AUTHOR) |
| المصدر: |
Oral Oncology. Mar2020, Vol. 102, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*SQUAMOUS cell carcinoma, *TREATMENT effectiveness, *HEAD & neck cancer, *OROPHARYNGEAL cancer, *THERAPEUTIC use of antineoplastic agents, *HEAD tumors, *PLATINUM compounds, *RESEARCH, *CONFIDENCE intervals, *RESEARCH methodology, *CANCER relapse, *RETROSPECTIVE studies, *MEDICAL cooperation, *EVALUATION research, *FLUOROURACIL, *METHOTREXATE, *HYDROCARBONS, *COMPARATIVE studies, *KAPLAN-Meier estimator, *NECK tumors |
| مصطلحات جغرافية: |
EUROPE, TAIWAN, SOUTH Korea, CANADA, BRAZIL, AUSTRALIA |
| مستخلص: |
Objectives: Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting.Materials and Methods: A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data.Results: Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54-67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0-1; 32% had oral cavity and 30% oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based combinations (73%), including platinum + 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%), or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%) and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% confidence interval [CI]: 21.5-24.6 months). Median real-world overall survival was only 8.0 months (95% CI: 7.0-8.0), with one-year survival reaching only 30.9% (95% CI: 27.5-34.3).Conclusion: Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
